ONE of the companies in the final is the Envision Pharma Group, a leading medical affairs-focused scientific communications and technology solutions provider headquartered in Horsham.

Founded in 2001, the business now employs approximately 550 people with a truly global operation spread across 12 offices in the UK, USA, Japan and Australia.

The unique selling point of Envision has always been the coupling of scientific communications with purpose-built software to deliver industry-leading levels of service to clients.

As with many start-ups Envision was heavily reliant on a single, albeit large, client account during its formative years.

However, growth was accompanied by diversification and their client list now boasts 18 of the top 20 pharma companies in the world.

Growth has also been driven by the expansion of core services beyond the realm of medical publications, with the addition of capabilities in market access, health economics, medical strategy and communications, and digital solutions.

Founder and current CEO Brian Hepburn said: “Envision’s growth has always been dependent on the high-quality scientific outputs, exemplary levels of service and industry-leading software that we provide to our clients on a daily basis.

“Therefore our continued expansion is truly a team effort, and nomination for this award reflects the efforts of every one of our employees.

“We are always looking for talented individuals to join our service and software-development teams but are especially proud of our 93 per cent year-on-year staff retention rate.

“This is an almost unheard of level of retention in our industry and I feel, reflects our company ethos and the share scheme that allows our employees to become part-owners of the company.”

Meanwhile, Dr Rebecca Lew, from ProScribe, part of the Envision Pharma Group, delivered the Best of ISMPP session at a recent meeting in Tokyo and Singapore.

These meetings were a mixture of presentations and round table discussions designed to increase the awareness of the Good Publications Practice Guidelines (GPP3) in the Asia Pacific region and the practicalities of their implementation.

In January the company acquired Curo Consulting Ltd, a global pharma market access consultancy whose services are supported by innovative software solutions.

These include purpose-built technologies that will augment Envision’s range of industry-leading technology solutions.

Envision’s CEO Brian Hepburn said: “Curo’s consulting expertise and software products will ensure we offer optimal evidence communication strategies to our clients.”